X
Celltrion/Teva Rituxan biosimilar edges closer to US approval
https://pharmaphorum.com/news/celltrion-teva-rituxan-biosimilar-edges-closer-to-us-approval/
Celltrion
Biosimilars underused in rheumatoid arthritis on the NHS – experts
Experts call for lower disease activity threshold for biologic drugs
Celltrion hopes to outdo inflammatory disease rivals with SC infliximab
Drugmaker could file in EU in coming weeks, according to report
FDA rejects Teva/Celltrion biosimilars
Regulator cites issues with manufacturing plant
Mundipharma to market Herceptin biosimilar in key EU markets
Mundipharma’s third biosimilar tie-up with Celltrion
Pfizer’s rituximab biosimilar gets late-stage trial boost
Phase 3 success sets up showdown with Roche, Sandoz, and Celltrion
Roche’s Herceptin facing further biosimilar threats in US
Breast cancer blockbuster facing potential trio of US competitors.
1 2
